NCT00171249View on ClinicalTrials.gov

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

293

Participants

Timeline

Start Date

August 9, 1999

Primary Completion Date

September 23, 2013

Study Completion Date

September 23, 2013

Conditions
Philadelphia Positive Chronic Myeloid LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia
Interventions
DRUG

STI571 400 mg

STI571 capsules and tablets

DRUG

STI571 600 mg

STI571 capsules and tablets

Trial Locations (12)

10021

New York Presbyterian Hospital, New York

77030

MD Anderson Cancer Center, University of Texas, Houston

97239

Oregon Health & Sciences University, Portland

02115

Dana Faber Cancer Institute, Boston

Unknown

Novartis Investigative Site, Pessac

Novartis Investigative Site, Poitiers

Novartis Investigative Site, Frankfurt

Novartis Investigative Site, Leipzig

Novartis Investigative Site, Mainz

Novartis Investigative Site, Mannheim

Novartis Investigative Site, Monza

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY